Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
JcSf9sBf27ytngYS